Based on data from a retrospective cohort study (N=238,335) that used Optum Clinformatics Data Mart Dataset to assess female outpatients aged ≥18 with uUTI empirically treated with oral ABX between October 2015 and September 2021. This study found that 12.3% of patients had evidence of TF.1
Based on data from a retrospective cohort study (N=376,004) that used Optum EHR data to assess female outpatients aged ≥12 with uUTI empirically treated with oral ABX between January 2017 and September 2022. This study found that 16.7% of patients had evidence of TF.2,3
Patients with an uncomplicated UTI had a documented uUTI diagnosis code (ICD-10-CM: N30.00, N30.01, N30.9, or N39.0) in an outpatient ambulatory/emergency department setting and no evidence of a complicated UTI.1-3
Additional clinical intervention may have included a second oral ABX prescription, administration of intravenous ABX, or an ED visit or inpatient stay with a new primary diagnosis of UTI.1-3
Defined as a diagnosis of recurrent UTI, identified in clinician notes, or as two UTIs in the past 6 months or three UTIs in the past 12 months, including the index uUTI diagnosis.3
During the 12-month baseline period, not including the index date, the date of the first empirically prescribed oral antibiotic ± 5 days of a randomly selected uUTI diagnosis.3
Adjusted rate ratios were estimated from multivariable generalized linear models with negative binomial distribution to account for overdispersion and adjusting for demographics as well as clinical characteristics with a standardized difference >20% between the TF cohort and the no TF cohort.2
UTI-related ED visits: TF, 23.3% (14,656/62,873); no TF, 15.8% (49,518/313,131).2
uUTI-related costs were defined as treatment for patients with a uUTI diagnosis during the 28-day uUTI episode and included: inpatient stay costs, outpatient costs, and prescription costs.1
Franklin M, Emden M, Kautz S, et al. Poster 2839 presented at: IDWeek 2023; October 11-15, 2023; Boston, MA.
Fromer DL, Luck M, Mahendran M, et al. Abstract 215900. Presented at: IDWeek 2024; October 16–19, 2024; Los Angeles, CA.
Fromer DL, Luck ME, Cheng WY, et al. Risk Factors for Empiric Treatment Failure in US Female Outpatients with Uncomplicated Urinary Tract Infection: an Observational Study. J Gen Intern Med. Published online October 2, 2024. doi:10.1007/s11606-024-09029-6
Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU Guideline. J Urol. 2019;202(2);282-289. doi:10.1097/JU.0000000000000296